YUQORI YOG‘LI RATSION VA SEFTRIAKSON ANTIBIOTIGINING QO‘SHMA TA’SIRIDA GEPATOTSITLAR SITOLIZI FERMENTLARI FAOLLIGI O‘ZGARISHLARINING PATOFIZIOLOGIK ASOSLARI
Keywords:
jigar yog‘li gepatozi, seftriakson, yuqori yog‘li ratsion, ALT, ASTAbstract
Tadqiqotda yuqori yog‘li ratsion va seftriaksonni bir vaqtda qo‘llash gepatotsitlar sitolizi bilan bog‘liq biokimyoviy ko‘rsatkichlarga qanday ta’sir qilishi baholandi. Tajribaga 160 ta oq zotsiz erkak kalamush jalb qilinib, ular to‘rtta guruhga ajratildi: yuqori yog‘li ratsion va seftriakson birgalikda qo‘llangan guruh, faqat yuqori yog‘li ratsion olgan guruh, oddiy ratsiondagi nazorat guruhi hamda oddiy ratsion fonida seftriakson olgan guruh. Seftriakson tajribaning 10-kunidan boshlab 10 kun davomida yuborildi. Qon zardobida alaninaminotransferaza (ALT), aspartataminotransferaza (AST) va laktatdegidrogenaza (LDG) faolligi aniqlandi, De Ritis koeffitsiyenti hamda qo‘shma ta’sirni baholash uchun potensiatsiya koeffitsiyenti hisoblandi. Yuqori yog‘li ratsion va seftriakson birgalikda qo‘llangan guruhda ALT nazoratga nisbatan 2,27, AST 1,83, LDG esa 23,24 barobar oshdi. Faqat yuqori yog‘li ratsion olgan hayvonlarda mos ko‘rsatkichlar 1,75; 1,44 va 13,14 barobarni tashkil etdi. Oddiy ratsion fonida seftriaksonning o‘zi LDG faolligini 5,42 barobar oshirdi. Potensiatsiya koeffitsiyenti ALT uchun 1,19, AST uchun 1,28 va LDG uchun 1,34 bo‘ldi. Natijalar yuqori yog‘li ratsion fonida seftriakson qo‘shilishi fermentativ siljishlarni kuchaytirishini, ayniqsa LDG o‘zgarishi yaqqol ekanini ko‘rsatdi. Ushbu ma’lumotlar metabolik xavf mavjud sharoitda antibakterial davolash vaqtida jigar fermentlarini dinamik nazorat qilish zarurligini asoslaydi.
Downloads
References
1. Rinella M.E., Lazarus J.V., Ratziu V. va boshqalar. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Journal of Hepatology, 2023, 79(6), 1542–1556. https://www.journal-of-hepatology.eu/article/S0168-8278(23)00418-X/fulltext
2. Zhou J., Tripathi M., Sinha R.A. va boshqalar. The Role of Gut-Derived Lipopolysaccharides and the Intestinal Barrier in Fatty Liver Diseases. Journal of Gastrointestinal Surgery, 2022, 26(3), 671–683. https://pubmed.ncbi.nlm.nih.gov/34734369/
3. Rau M., Geier A. va boshqalar. Deciphering the Gut–Liver Axis: A Comprehensive Scientific Review of Non-Alcoholic Fatty Liver Disease. Livers, 2024, 4(3), 32. https://www.mdpi.com/2673-4389/4/3/32
4. Stankiewicz-Drogon A., Skrzypczak-Zielinska M., Dobrowolska A. va boshqalar. Diet-Induced Rat Model of Gradual Development of Non-Alcoholic Fatty Liver Disease with Lipopolysaccharides Secretion. Diagnostics, 2019, 9(4), 205. https://www.mdpi.com/2075-4418/9/4/205
5. Pezzino S., Sofia M., Faletra G. va boshqalar. Gut–Liver Axis and Non-Alcoholic Fatty Liver Disease: A Vicious Circle of Dysfunctions Orchestrated by the Gut Microbiome. Biology, 2022, 11(11), 1622. https://doi.org/10.3390/biology11111622
6. Xia J., Jin Y., Hong Y. va boshqalar. Effects of gut microbiota dysbiosis on the metabolism and pharmacokinetics of losartan in rats: from endogenous to ceftriaxone-induced dysbiosis. Frontiers in Microbiology, 2025. https://doi.org/10.3389/fmicb.2025.1693247
7. Sanchez J.J., Namba M.D., Augur I.F. va boshqalar. Ceftriaxone alters the gut microbiome composition and reduces alcohol intake in male and female Sprague–Dawley rats. Alcohol, 2024. https://www.sciencedirect.com/science/article/abs/pii/S0741832924000156
8. Yamamoto A., Kawaguchi T. va boshqalar. An investigation of broad-spectrum antibiotic-induced liver injury based on the FDA Adverse Event Reporting System and retrospective observational study. Scientific Reports, 2024, 14. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11303562/
9. Gao H., Shu Q., Chen J. va boshqalar. Antibiotic Exposure Has Sex-Dependent Effects on the Gut Microbiota and Metabolism of Short-Chain Fatty Acids and Amino Acids in Mice. mSystems, 2019, 4(4). https://doi.org/10.1128/mSystems.00048-19
10. Ma Z., Zhang Y., Li Q. va boshqalar. Beneficial effects of paeoniflorin on non-alcoholic fatty liver disease induced by high-fat diet in rats. Scientific Reports, 2017, 7. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5353673/
11. Kolaric T.O., Nincevic V., Kuna L. va boshqalar. NAFLD/MASLD and the Gut-Liver Axis: From Pathogenesis to Treatment Options. Nutrients, 2024, 16(14). https://pubmed.ncbi.nlm.nih.gov/39057689/
12. Ferolla S.M., Armiliato G.N., Couto C.A., Ferrari T.C. Small Intestinal Bacterial Overgrowth and Non-Alcoholic Fatty Liver Disease: What Do We Know in 2023? Nutrients, 2023, 15(6). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10052062/
13. Ferro D., Baratta F., Pastori D. va boshqalar. Gut microbiota heterogeneity in non-alcoholic fatty liver disease: a narrative review of drivers, mechanisms, and clinical relevance. Frontiers in Microbiology, 2025. https://www.frontiersin.org/journals/microbiology/articles/10.3389/ fmicb.2025.1645298/full
14. Polyzos S.A., Kountouras J. va boshqalar. Partial validation of a six-month high-fat diet and fructose-glucose drink combination as a mouse model of nonalcoholic fatty liver disease. Endocrine, 2024. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11291610/
15. Sharma A., Mehta V. va boshqalar. Comparative Evaluation of the Effects of Oral Anti-hyperglycemic Agents and an Ayurvedic Hepatoprotective Agent in a Rat Model of Non-alcoholic Fatty Liver Disease. Cureus, 2026. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12828853/
16. Chen T.C., Yen C.H. va boshqalar. Lactobacillus rhamnosus Ameliorates Dyslipidemia and Liver Steatosis in a Rat Model Fed High-Fat Diet. Nutrients, 2025. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12537184/
17. Alhumaid S., Al Mutair A. va boshqalar. Nafcillin-Induced Hepatic Injury: A Case Report and Literature Review. Cureus, 2021. https://pmc.ncbi.nlm.nih.gov/articles/PMC7894250/
18. Alqahtani A., Mohamed A. va boshqalar. Drug-Induced Liver Injury Caused by Amoxicillin/Clavulanate. Cureus, 2020. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7819498/
19. Song Q., Zhang X. va boshqalar. Persistent gut microbiota dysbiosis and metabolic remodeling after ceftriaxone exposure in mice: a cross-study re-analysis. Frontiers in Cellular and Infection Microbiology, 2026. https://www.frontiersin.org/journals/cellular-and-infection-microbiology/articles/10.3389/fcimb.2026.1822390/full
20. Nier A., Engstler A.J., Maier I.B., Bergheim I. Association between endotoxemia and histological features of nonalcoholic fatty liver disease. World Journal of Gastroenterology, 2017, 23(4). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5292346/
